The woods are lovely, dark, and deep,
But I have promises to keep,
And miles to go before I sleep,
And miles to go before I sleep.
—Robert Frost
True to the publication of diverse issues that comprise and challenge the field of
allergy and immunology and the allergist/immunologist, this issue of the Allergy and
Asthma Proceedings features a spectrum of articles that we hope will provide greater
insight and clinical utility for the readership in seven major areas of current research.
These include the following: asthma, allergens and allergy immunotherapy, the interplay
of environment on the development of allergic disease, hereditary angioedema, drug
allergy and immunodeficiency, and the inner city asthma epidemic.
The idea that certain features of life in poor urban areas could promote asthma dates
back to more than a half century ago when researchers began to describe an “inner-city
asthma epidemic” of high asthma prevalence and morbidity in disadvantaged populations
living in poor areas of large cities. In more recent years, major research efforts
are being directed to the study of the causes of inner city asthma that contribute
to high morbidity and mortality, particularly to vulnerable children who live in these
inner-city disadvantaged populations. In school children, it manifests as absences
and decreased academic performance attributable to frequent asthma exacerbations.
In an insightful article, Szefler
1
used a case-based format to overview the unmet needs associated with inner-city asthma
and discussed the myriad of factors that contribute to asthma exacerbations in this
setting, including obesity, allergic sensitization, and lack of medication adherence.
His report offers novel strategies to predict and prevent seasonal exacerbations of
asthma, use new medications, and initiate school-centered asthma programs designed
to assure optimal adherence.
Because of the great interest and importance of the myriad of environmental, medical,
and socioeconomic asthma risk factors that contribute to the “inner-city asthma epidemic,”
the article by Szefler
1
was chosen for this issue's “For the Patient” section. The topic holds special interest
and offers an important role for the allergist/immunologist in addressing this important
national problem and presented both promises to keep and challenges to be met. The
challenges are before us, and, in the ensuing decades, the allergist/immunologist
will have a dual responsibility: one is scientific, the other is social. First, as
a clinician at the translational interface of science and clinical applicability,
the allergist/immunologist must take an active role in identifying substantive asthma
and allergy risk factors, and new areas for clinical application to patient management
unimaginable in past years. The promise of allergy immunology is to assure that the
health of our patients, and particularly of children, flourishes and is attended to
by professionals with competencies and skills necessary to provide optimal patient
management. The challenge for the allergist/immunologist then is to guarantee that
the promise is kept. The article by Szefler
1
is a gentle reminder that the allergist/immunologist must also assume the responsibility
as physician-educator and child advocate that children might prosper on this earth.
Another innovative asthma treatment strategy that is addressed in this issue of the
Proceedings is the use of a single inhaler (inhaled corticosteroid/long-acting β-agonist
combination) for both maintenance and reliever therapy. Lin et al.
2
performed a 12-week, multicenter, open-label therapeutic phase IV study in which patients
with partially controlled or uncontrolled asthma were switched from their usual asthma
treatment to a budesonide/formoterol (160/4.5 μg, one inhalation twice daily and as
needed) regimen. The authors found that asthma control and quality of life improved
in Chinese patients who received treatment with the budesonide/formoterol maintenance
and reliever therapy.
Inhaled corticosteroids, although efficacious for the treatment of persistent asthma,
have the potential for adverse effects, including adrenal suppression when used at
high doses or in susceptible individuals. Kowalski et al.
3
performed a systematic review and quantitative analysis of 64 published studies with
the goal of synthesizing all currently available studies on novel, freon-free inhaled
corticosteroid preparations. From their analysis, they reported that the strongest
dose-response urinary cortisol suppression was observed in patients treated with beclomethasone,
followed by fluticasone and budesonide, but that no significant urinary cortisol suppression
was associated with ciclesonide.
Although antioxidant dietary supplements have long been proposed for the treatment
of asthma, no convincing evidence has been available. Tenero et al.
4
attempted to provide efficacy data by retrospectively evaluating the effect of an
antioxidant dietary supplement on exhaled nitric oxide and lung function over a 1-month
period in 47 pediatric patients on stable antiasthma treatment. Based on their findings,
the authors indicated that supplementation with a nutraceutical regimen of antioxidants
and anti-inflammatory compounds may be associated with reduced airway inflammation.
Omalizumab, the anti- IgE flagship monoclonal antibody, has established therapeutic
efficacy for the treatment of patients 12 years of age and older with moderate-to-severe
persistent allergic asthma who are not controlled on inhaled steroids. More recent
studies demonstrated that omalizumab may also provide benefit in the management of
selected patients with chronic rhinosinusitis (CRS). In this issue of the Proceedings,
Clavenna et al.
5
performed a retrospective case-control study to examine the clinical efficacy of omalizumab
in patients with both asthma and CRS compared with those with asthma alone. The authors
reported that improved pulmonary function associated with omalizumab treatment was
more likely to be observed in patients with both asthma and comorbid CRS than in those
without CRS.
There exists a great need and considerable potential clinical utility to identify
biomarkers that would serve as predictors of favorable responses of patients with
severe asthma to treatments, e.g., omalizumab. In this issue of the Proceedings, Tsybikov
et al.
6
evaluated chronic rhinitis biomarkers in an attempt to better assess upper airway
inflammatory phenotypes in subjects with allergic rhinitis, nonallergic rhinitis,
and CRS. They propose that chronic rhinitis can be categorized into several disease
phenotypes by assessment of four chronic rhinitis biomarkers: endothelin-1, thymus
and activation-regulated chemokine (TARC/CCL17), and α-defensins.
Transitioning from asthma to a focus on allergens and allergy immunotherapy are two
articles of studies that examined the diagnostic dependence of antibody levels and
allergen potency on allergic disease management. The first article, by Ciprandi et
al.,
7
investigated the practical role of Bet v 1 IgE in differentiating birch allergy from
oral allergy syndrome. The authors indicated that a serum IgE cutoff value to Bet
v 1 could be a useful marker for differentiating among different birch pollen sensitization
phenotypes. The second article addressed a comparison of the potency of allergy extracts
used in Europe compared with those used in the United States. Larenas-Linnemann and
Mosges
8
performed further data analysis to facilitate interpretation of SLIT dosing, as recommended
by European manufacturers, relative to U.S. SCIT maintenance dosing. They reported
that, for more than half of the products, SLIT is not “high dose,” as has originally
been recommended; however, how this potency relates to efficacy is not clear.
The association of the environment and infectious disease on allergic disease expression
is addressed in three articles found within this issue. Kim et al.
9
demonstrated that exposure to elevated carbon monoxide levels during infancy increases
the risk of development of allergic rhinitis and of atopic dermatitis symptoms in
South Korean children. Kim et al.
10
investigated the effects of ethnicity and environmental exposures on eczema in Hispanic
white and non-Hispanic white children who participated in the Southern California
Children's Health Study. They reported finding an ethnic difference, with Hispanic
white children having a lower prevalence of eczema than non-Hispanic white children,
which could not be accounted for by sociodemographic differences. The effects of parental
history of allergic disease and indoor environmental exposures on eczema varied by
ethnicity indicating that the etiology of eczema may differ in different ethnic groups.
The role of infectious disease was next examined by Imbalzano et al.,
11
who performed a systematic review about the association between urticaria and viral
infections. They presented their data analysis, which indicated viral infection as
a potential trigger and sometimes as the main etiologic agent in causing acute or
chronic urticaria.
Unlike chronic urticaria, hereditary angioedema is a rare and potentially life-threatening
disease characterized by recurrent angioedema, which has been a frequently visited
theme in recent issues of the Proceedings.
12–27
Abdominal symptoms of hereditary angioedema typically mimic numerous abdominal emergencies
and may delay the correct diagnosis and inappropriate treatments. Ucar et al.
28
report on the difficulties experienced by patients with hereditary angioedema in Turkish
emergency departments, which is representative of the unmet needs reported globally.
Drug allergy, in particular, nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity
has been a recurrent theme in the Proceedings.
29–33 Within this issue, Topal et al.
34 sought to determine the diagnostic value of the clinical history and also to determine
safe alternative medications in 64 children who were evaluated for immediate-type
reactions to NSAIDs. They reported that two historical features, the emergence of
symptoms within an hour of taking the drug and the presence of hypersensitivity to
multiple NSAIDs increased the possibility of true NSAID hypersensitivity. In addition,
they identified three safe alternative drugs in patients with multiple NSAID hypersensitivity:
nimesulide, low-dose acetaminophen, and tolmetin sodium.
This issue's Patient-Oriented Problem Solving “POPS” case presentation shifts our
focus to immunodeficiency. The POPS case presentation is a recurring feature of the
Proceedings, which, as per tradition, is written by an allergy/immunology fellow-in-training
from one of the U.S. allergy/immunology training programs. The purpose of the POPS
series is to provide an innovative and practical learning experience for the novice
allergist/immunologist in-training by using a didactic format of clinical presentation
and deductive reasoning. In this issue's POPS, Buyantseva et al.,35 from the Penn
State Hershey Medical Center, lead the reader through this process by describing the
evaluation of a 73-year-old woman who presented with chronic watery diarrhea, weight
loss, and frequent sinus and nail fungal infections. This case report illustrated
the complexity of the differential diagnostic process for this clinical presentation
and the importance of a detailed history, physical examination, and appropriate laboratory
assessment in arriving at a correct diagnosis.
In summary, the collection of articles found within the pages of this issue provides
further insight into important allergic, cutaneous, and respiratory disorders that
afflict patients whom the allergist/immunologist serve. In keeping with the overall
mission of the Proceedings, which is to distribute timely information regarding advancements
in the knowledge and practice of allergy, asthma, and immunology to clinicians entrusted
with the care of patients, it is our hope that the articles found within this issue
will help foster enhanced patient management through efficient workup and optimal
therapy for a great diversity of clinical problems. On behalf of the editorial board,
we hope you enjoy the diversity of literature offered in this issue of the Proceedings.